Rilotumumab — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	3	12	—	—	Oct 27, 2008
Malignant Gastric Neoplasm	Phase3	Phase 3	2	4	—	—	2009-02
Malignant Lung Neoplasm	Phase3	Phase 3	1	2	—	—	Dec 2, 2008
Malignant Central Nervous System Neoplasm	Phase2	Phase 2	0	1

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MET Overexpression1
Rilotumumab	Gastric Adenocarcinoma

Clinical trials

Trials with this intervention (13)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–13 of 13 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00791154	QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC)	terminated	Phase 1 / Phase 2	213	NantCell, Inc.INDUSTRY	0	Aug 23, 2024	clinicaltrials
NCT00788957	Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)